brincidofovir   Click here for help

GtoPdb Ligand ID: 11556

Synonyms: CMX-001 | CMX001 | HDP-CDV | hexadecyloxypropyl cidofovir | Tembexa®
Approved drug
brincidofovir is an approved drug (FDA (2021))
Compound class: Synthetic organic
Comment: Brincidofovir is an orally bioavailable, lipid-conjugated (to enhance cellular penetration) ester prodrug of the acyclic nucleoside monophosphate antiviral cidofovir. The active metabolite is cidofovir diphosphate, which disrupts viral DNA polymerase activity and viral DNA replication. Brincidofovir has been investigated for infections caused by several virus families, including cytomegalovirus (CMV), BK virus (BKV), adenoviruses (AdV) [1], HPV [4], and Epstein-Barr virus (EBV), as well as for smallpox (Variola) infections.
A molecular docking study has indicated that brincidofovir interacts with both host ACE2 and SARS-CoV-2 3C-like (main) protease [2]. Further studies would be required to validate brincidofovir as a potential therapy for SARS-CoV-2 infection.

brincidofovir is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 3
Rotatable bonds 26
Topological polar surface area 155.94
Molecular weight 561.35
XLogP 7.01
No. Lipinski's rules broken 2

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CCCCCCCCCCCCCCCCOCCCOP(=O)(CO[C@@H](Cn1ccc(nc1=O)N)CO)O
Isomeric SMILES CCCCCCCCCCCCCCCCOCCCOP(=O)(CO[C@@H](Cn1ccc(nc1=O)N)CO)O
InChI InChI=1S/C27H52N3O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-35-20-16-21-37-38(33,34)24-36-25(23-31)22-30-18-17-26(28)29-27(30)32/h17-18,25,31H,2-16,19-24H2,1H3,(H,33,34)(H2,28,29,32)/t25-/m0/s1
InChI Key WXJFKKQWPMNTIM-VWLOTQADSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Brincidofovir was approved by the FDA in June 2021, as a treatment for smallpox; principally intended for use if smallpox were to be used as a bioterrorism agent, or to combat its reappearance through accidental release. The effectiveness of brincidofovir for human smallpox infections is predicted from relevant animal models [3], since naturally occurring human infections are rare and it would be unethical to conduct challenge trials in human subjects. Brincidofovir holds EMA orphan designations (all granted in 2016) for prevention of cytomegalovirus disease, treatment of smallpox and treatment of adenovirus infection in immunocompromised patients.